Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Humacyte announced positive interim results from its V012 Phase 3 study showing that its acellular tissue engineered vessel (ATEV) provides significantly more catheter-free days compared to the current standard of care, autologous AV fistula, in female dialysis patients. The trial met its primary endpoint with a strong statistical significance, lea…